Info

🌱 來自：treatment and prognosis of multiple myeloma (MM)

treatment of multiple myeloma (MM)

• CASSIOPEIA D-VRd

• PERSEUS D-VTd

• IMROZ

• incl. proteasome inhibitors:

  • bortezomib (V)
  • carfilzomib (K)
  • ixazomib (I);

• immunomodulators:

  • lenalidomide (R)
  • thalidomide (T),
  • pomalidomide (P);

• immunotherapy:

  • daratumumab (anti-CD38, Dara),
  • elotuzumab (anti-SLAMF7, Elo)

• Other active drugs:

  • dexamethasone (D)
  • melphalan,
  • panobinostat,
  • cyclophosphamide

Induction Rx w/ best response rate

• proteasome inhib (V or K) + immunomod (eg, R).

• Triplet Rx ↑ OS vs. double (Lancet 2017;389:519).

• RVD most common regimen in US;

• KRD if high-risk (NEJM 2014;371:906 & 2016;374:1621).

• Dara-RD an option (NEJM 2019;380:2104).

• Quad Rx (Dara-RVD) may improve response rates (Blood 2020;136:936).

• If not transplant eligible-of-treatment of multiple myeloma (MM)

• If transplant eligible-of-treatment of multiple myeloma (MM)